EARLY NIVOLUMAB ADDITION TO REGORAFENIB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA PROGRESSING UNDER 1ST LINE THERAPY (GOING TRIAL). INTERIM ANALYSIS AND SAFETY PROFILE
Marco Sanduzzi Zamparelli 1
Ana Matilla 2
José Luis Lledo 3
Sergio Muñoz-Martínez 3
Maria Varela 4
Mercedes Iñarrairaegui 5
Christie Perelló 6
Beatriz Mínguez Rodríguez 7
Neus Llarch 7
laura marquez 8
Antonio Guerrero 8
Gemma Iserte 8
Andrés Castaño-García 9
Laura Carrión 9
Jordi Rimola 10
Ángeles García-Criado 10
Gema Domenech 11
Loreto Boix 11
Jordi Bruix 11
Maria Reig 11
1 BCLC group. Liver Unit, Hospital Clinic of Barcelona, IDIBAPS. CIBERehd, University of Barcelona, Barcelona, Spain
2 Gastroenterology Department, Hospital General Universitario Gregorio Marañón, CIBERehd, Madrid, Spain
3 Gastroenterology & Hepatology Department, Hospital Universitario Ramón y Cajal, CIBERehd, Madrid
4 Hospital Universitario Central de Asturias, Oviedo, Spain
5 Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra IDISNA and CIBEREHD, Navarra, Spain
6 Gastroenterology Department. Hepatology Unit, Hospital Universitario Puerta de Hierro, IDIPHISA, CIBERehd, Madrid, Spain
7 Liver Unit, Hospital Universitari Vall d'Hebron, Liver Diseases Research Group, Vall d'Hebron Institute of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus. CIBERehd, Universitat Autònoma de B
8 Gastroenterology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
9 Liver Unit, Gastroenterology Department, Hospital Universitario Central de Asturias, IUOPA, FINBA, Oviedo, Spain
10 BCLC Group, Radiology Department, Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain
11 Medical Statistics Core Facility, IDIBAPS-Hospital Clínic, Barcelona, Spain, Barcelona, Spain
Topic
Hepatobiliary, Histopathology
Conference
UEG Week 2022
Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]